Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | RAB9A | P51151 | 5/20 | 0.35 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | HPGD | P15428 | 4/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34471053 | 0.72 | SLC6A3 (0.37) | MEN1KMT2AMAPK1KDM4EALDH1A1 | |
| SCHEMBL34470787 | 0.72 | F2 (0.43) | MEN1KMT2AKDM4EALDH1A1RAB9A | |
| SCHEMBL26690301 | 0.72 | ALDH1A1 (0.36) | SMN1; SMN2KMT2AKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL24030294 | 0.69 | MEN1 (0.36) | SMN1; SMN2MEN1KMT2AMAPK1KDM4E | |
| SCHEMBL34471792 | 0.69 | L3MBTL1 (0.34) | SMN1; SMN2MEN1KMT2AMAPK1KDM4E | |
| SCHEMBL14738044 | 0.68 | SSTR4 (0.43) | SMN1; SMN2MEN1KMT2AMAPK1KDM4E | |
| SCHEMBL29277572 | 0.68 | TSHR (0.37) | SMN1; SMN2MEN1KMT2AMAPK1KDM4E | |
| SCHEMBL2085574 | 0.68 | MAPK1 (0.45) | KMT2AMAPK1KDM4EALDH1A1RAB9A | |
| SCHEMBL31479337 | 0.67 | KDM4E (0.35) | MAPK1KDM4EALDH1A1RAB9AMAPT | |
| SCHEMBL25515640 | 0.67 | MAPT (0.48) | SMN1; SMN2MEN1KMT2AMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4526298-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | F. Hoffmann-La Roche AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| US-20250074913-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-06 | — | — | US | disclosed |
| CN-119212989-A | Pyrazole derivatives as STING agonists | 豪夫迈·罗氏有限公司 | 2024-12-27 | — | — | CN | disclosed |
| WO-2023222644-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023222644-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074913-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | STING1, CGAS, MAVS | SMN1; SMN2 4089/4885MEN1 2237/4885KMT2A 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.